Editas Medicine Co-Founder Develops Novel Approach To Increase Specificity Of CRISPR/Cas9 Technology; Findings Published In Nature Biotechnology

Published: Jan 27, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a transformative genome editing company, today announced new published research from company co-founder J. Keith Joung, M.D., Ph.D., demonstrating the ability of truncated guide RNAs (tru-gRNAs) to increase the specificity of the novel genome editing technology CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9). This approach has the potential to further refine Editas' CRISPR/Cas9 technology and enhance the company’s ability to knock-out, knock-down or selectively edit disease-causing genes. The paper was published in the current online edition of Nature Biotechnology1 and co-authored by Dr. Joung, who is associate chief of pathology for research and an associate pathologist at Massachusetts General Hospital and associate professor of pathology at Harvard Medical School.

Help employers find you! Check out all the jobs and post your resume.

Back to news